For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

Pancreatic cancer has long been one of the most lethal diagnoses in medicine, largely because it spreads early and hides from both scans and drugs. Now researchers are testing a new kind of ...

Novocure (Nasdaq:NVCR) announced that the FDA granted approval for its Optune Pax treatment for advanced pancreatic cancer.

With this decision, Optune Pax becomes the first new FDA-approved treatment for locally advanced pancreatic cancer in decades ...

New implantable pancreatic cancer treatment honoured in the Problem Solver category at the Shaping Australia Awards University of Wollongong ...

Researchers say an immunotherapy they used represents a significant step forward and could lead to new treatment options, even for other forms of cancer ...

By adding ANPEP and PIGR to existing markers, researchers created a blood test that accurately identified early pancreatic ...

DURIPANC is an investigator-initiated, exploratory, open-label, single-center study, and 18 subjects have enrolled in the study so far. The clinical trial is a joint collaboration between AIM, ...

Pancreatic cancer treatment relies on surgery, chemotherapy, and radiation, with surgery for non-metastatic, technically resectable tumors. Advances in chemotherapy, neoadjuvant approaches, and ...

A feature of pancreatic cancer cells' surroundings determines whether they grow fast or become resistant to chemotherapy, a ...